World’s Influential Leaders Making A Footprint in Pharma and Biotech, 2023.pdf

www.worldsleaders.com Vol. 11 | Issue 12 | November 2023
Creating Legacy in
Biotechnology
and Pharmaceuticals
INFLUENTIAL
LEADERS
Making A Footprint in
Pharma and Biotech, 2023
Founder/ CEO | Therabene
WORLD’S

World's Inuential Leaders Making A
Footprint in Pharma and Biotech, 2023
Hundreds of businesses make up the biotechnology
sector, which combines biology and technology to create
medications and associated goods for the treatment of
illnesses and ailments. The biotechnology sector of the
economy today include businesses that produce biofuels,
biomaterials, environmental controls, medical equipment
and diagnostics, and more.
Pharmaceutical businesses like Novo Nordisk and
Moderna are among the biggest in the market. These
businesses must go through drawn-out trial and approval
procedures for their goods, and they often concentrate on
developing and testing novel medicinal molecules for
medical applications. This implies that before learning if
a possible medication therapy is practical or lucrative,
investors sometimes have to wait months or even years.
In spite of the numerous obstacles that biotechnology
companies face, a number of businesses and their
executives have achieved success in the sector. World's
Leaders latest edition “World's Influential Leaders
Making a Footprint in Pharma and Biotech, 2023” has
featured success stories of renowned influential Pharma
and Biotech leaders whose expertise in leadership is
echoing globally. The cover has Mario DiPaola, Co-
Founder and CEO at Therebene, Inc, is an industry
veteran with a remarkable 25-year track record and has
left an indelible mark in the realm of life sciences.
Mario's journey through the biotechnology and
pharmaceutical industries is a testament to his dedication
and expertise. With a focus on basic research,
development, quality, manufacturing, and regulatory
functions in support of protein and small molecule drug
development, he has navigated the complex world of
therapeutic advancement with remarkable success. His
extensive experience includes involvement in the
development and regulatory filings (BLA/eCTD) of
several approved therapeutics, such as Alferon-N,
Amevive, and Sucraid, which have brought hope and
healing to countless individuals.
Also, while you flip through the pages, don't forget to read
the articles created by our in-house editorial staff and
industryexperts.
Achieving New Feats in
Pharma and Biotech
Have a lovely read!

Copyright 2023 WORLD’S LEADERS Media Tech LLC, All rights reserved. The content and images used in this magazine
should not be reproduced or transmitted in any form or by any means, electronic, mechanical,
photocopying, recording or otherwise, without prior permission from WORLD’S LEADERS Reprint rights
remain solely with WORLD’S LEADERS.
3296 Westerville Rd #250, Columbus, OH 43224, USA
Follow us on :
Editor-in-Chief Steve Sanchez
Managing Editor Jagdish Chincholikar
Executive Editor Nicole Williams
Assistant Editor Gayatri Bhujbal
Art & Design Director Jack Anderson
Business Development Manager Mia Oliver
Business Development Executive Natalie, Jerrey
Associate Designer Kevin Rust
Digital Marketing Manager Victor Clarke
Sales Manager Casey Simpson, Irfan Shekh
Marketing Manager Tom Swann
Technical Specialist Barry Jones
Circulation Manager Danny Parker
CREDIT PAGE
November 2023

Creating Legacy in Biotechnology and Pharmaceuticals
08
Cover
Story
Mario DiPaola

Dr. Rupert Ecker
Heidi Lindner
Kevin MacRitchie
Raman Singh
Paul Edalat
Oriol Segarra
Jahanara Miotto
Mitch Gould
Dr. Gabriel Serrano
50
46
42
36
32
28
24
18
14

COVER
STORY
08 | November 2023

In the ever-
evolving
landscape of
biotechnology
and
pharmaceuticals,
one name stands
out as a beacon of
experience and innovation. Mario
DiPaola, Co-Founder and CEO at
Therebene, Inc, is an industry veteran
with a remarkable 25-year track
record and has left an indelible mark
in the realm of life sciences.
Mario's journey through the
biotechnology and pharmaceutical
industries is a testament to his
dedication and expertise. With a
focus on basic research,
development, quality, manufacturing,
and regulatory functions in support
of protein and small molecule drug
development, he has navigated the
complex world of therapeutic
advancement with remarkable
success. His extensive experience
includes involvement in the
development and regulatory filings
(BLA/eCTD) of several approved
therapeutics, such as Alferon-N,
Amevive, and Sucraid, which have
brought hope and healing to
countless individuals.
Beyond the confines of laboratories
and regulatory processes, Mario's
impact extends to the world of
academia and research. With over 60
publications to his name and several
patents as a co-inventor, he has
played a pivotal role in advancing the
frontiers of science and innovation.
His work reflects a commitment to
exploring new horizons and pushing
the boundaries of what's possible in
the quest to improve human health.
Mario's entrepreneurial spirit is
another defining facet of his journey.
He has founded or co-founded
several companies, each with a
unique mission and vision. Blue
Stream Laboratories Inc., a company
he co-founded, achieved such
success that it was acquired by
Charles River Laboratories in 2016.
Higher-Order Technologies LLC,
which focuses on developing novel
analytical equipment, is yet another
example of his commitment to
pushing the envelope of technology
and discovery.
Approaching Targeted Disease
Treatment
Therabene, a biotechnology startup
founded in 2020, is pioneering the
development of high-potency, low-
toxicity targeted chemotherapeutic
agents known as "degraders”, also
referred to as PROTACs. These
degraders have the potential to treat
cancers, autoimmune diseases,
specific viral infections, and other
challenging conditions. This novel
approach to drug discovery extends
beyond traditional methods, which
focus on directly controlling protein
activity. To date, Therabene has
designed and synthesized around a
dozen degraders, with TB-003 and
TB-008 undergoing extensive in-
vitro evaluations. TB-003 has also
shown promising efficacy against
triple negative breast cancer in in-
vivo studies, highlighting the
innovative potential of degraders in
medical research and treatment.
The primary objective of the
company is to create degraders
targeting disease-associated proteins.
The initial target is CDK9, which
plays a direct role in multiple
malignancies, including breast,
ovarian, pancreatic, and other solid
tumors. The company's immediate
goal is to obtain approval for one of
its leading products in the United
States. Following this, expansion into
international markets is planned, with
a focus on Europe, Asia, Australia,
Canada, and eventually South
America. Therabene also intends to
extend its technology to target
proteins beyond CDK9, including
Myc and H/KRas proteins, among
others.
Principles for Growth and
Development
Mario's perspective on continuous
growth and development as a
business leader underscores several
key principles. Staying updated on
the latest trends, technologies, and
best practices in the biotech/pharma
industry is paramount. This involves
attending conferences, enrolling in
online courses when needed, and
actively seeking out mentoring
opportunities. Networking is also
emphasized as a critical step in
building strong professional
connections, achieved through
participation in industry events,
association memberships, and
interactions with fellow business
leaders. Networking can yield
valuable insights, collaboration
opportunities, and exposure to fresh
ideas.
Mario suggests that effective
leadership includes actively seeking
feedback from team members, peers,
and mentors. Constructive feedback
plays a vital role in identifying areas
In
10 | November 2023

for improvement and refining leadership styles.
Furthermore, embracing challenges and viewing them as
growth and learning opportunities is encouraged, as
overcoming challenges can enhance resilience and
problem-solving skills. Seeking mentorship from
established leaders can provide invaluable guidance,
support, and insights.
Mario acknowledges that the business landscape is ever-
evolving, and a successful leader must be adaptable and
open to change. Continually evaluating strategies and
being prepared to pivot when necessary is a critical
aspect of effective leadership.
In Mario's view, one challenge faced by emerging
leaders may be a lack of resilience to persevere,
particularly in adverse conditions. Additionally, some
emerging leaders may prioritize quick financial rewards
and swift exits over long-term growth and sustainability.
Pursuing Societal Equality and Health Equity
From a societal standpoint, Mario emphasizes the
importance of achieving greater social equality. This
involves promoting equal rights, diversity, and inclusion
to create a more harmonious and inclusive society.
In the field of Pharma and Biotech, Mario's aspiration is
for the development of better and more effective drugs
that are accessible to the entire population, rather than
limited to a select subset. This reflects a desire for more
equitable healthcare and medication access.
worldsleaders.com | 11

Regarding people's lives, Mario envisions several
improvements, including healthier lives driven by
enhanced nutrition, reduced prevalence of diseases, and
the availability of better and safer drugs to combat
various illnesses. This vision aligns with the pursuit of
overall well-being and health for individuals.
Leading with Vision
When it comes to building a team, Mario values qualities
such as ambition, commitment, and integrity as top
priorities. Strong work ethics, leadership skills, and
creativity in problem-solving are also highly sought
after, along with a genuine desire to make a positive
impact in the workplace and society as a whole.
Mario's role encompasses various significant
responsibilities within the organization:
Ÿ Overseeing the strategic direction of the organization
and formulating long-term plans.
Ÿ Creating, communicating, and implementing the
organization's vision and mission.
Ÿ Leading the development and implementation of the
overall organization's strategy.
Ÿ Seeking advice and guidance, when appropriate, from
a board of directors.
Ÿ Evaluating the organization's success in achieving its
goals.
Ÿ Exploring opportunities for fresh funding or the sale
of the company under circumstances that enhance
shareholders' value.
Ÿ
Additionally, one of Mario's more enjoyable tasks is
reviewing data and assisting the team in designing new
studies and strategies as needed.
Evolution of the Pharmaceutical Industry
According to Mario, the pharmaceutical industry has
experienced a significant transformation due to the
integration of digital technologies. Innovations like
predictive analytics, big data analysis, and AI-based tools
have provided companies with the means to revamp their
business processes, resulting in the more efficient and
faster production of drugs. Artificial intelligence has
played a crucial role in enhancing patient responsiveness
to medications. Consequently, pharmaceutical companies
have transitioned toward a more patient-centric
approach, offering applications that empower the public
to take charge of their health and interact more
effectively with pharmaceutical companies through
patient platforms.
Another noteworthy change in the industry, as
highlighted by Mario, is the globalization of
pharmaceuticals. Raw materials, excipients, and other
drug components are now sourced and manufactured on
an international scale, making them available on a global
market platform. This represents a significant shift in the
pharmaceutical sector. Additionally, over the past
decade, there has been a growing trend toward global
outsourcing of research capabilities and mass drug
manufacturing, catering to both developed and
developing markets.
Aspiring for Milestones
One of the most significant risks that Mario has
undertaken was the transition from being a company
employee to becoming an entrepreneur. This journey
involved starting various companies during economically
challenging times when funding opportunities were
scarce.
Looking ahead to the next five years, Mario anticipates
that Therabene will achieve regulatory approval for at
least one drug for the treatment of triple negative breast
cancer. There is also the possibility of gaining approval
for the treatment of ovarian cancer, marking a substantial
milestone in the company's trajectory.
12 | November 2023

Dr.Gabriel
Serrano
Pioneering Skin Care Innovation

For over four decades, Dr. Gabriel
Serrano has been at the forefront
of dermatology, leaving an
indelible mark on the industry. As
the esteemed owner of the
renowned Dermatology Clinics in
Valencia, Madrid, Dubai, Bogotá
and Bayahibe, bearing his name,
Dr. Serrano has built a legacy of
exceptional patient care and
groundbreaking innovation. In
fact, the Valencia clinic is
th
celebrating its 50 anniversary in
2023.
Driven by his deep understanding
of patients' skin needs, gained
through direct contact in his daily
practice, Dr. Serrano founded
Sesderma Laboratories in 1989.
With a commitment to
personalized care and attentive
listening, he embarked on a
journey to develop specialized
products that address a myriad of
skin concerns.
Sesderma, a leading Spanish
dermatological laboratory with a
remarkable 34-year history, has
emerged as a dominant force in
over 90 global markets. The
company is dedicated to intensive
research, development,
formulation, and manufacturing
of advanced dermocosmetic
products, nanonutraceuticals, and
medical-aesthetic cosmetics.
At the heart of Sesderma's success
lies a relentless pursuit of
research, development, and
innovation (R+D+I), driving the
creation of groundbreaking
solutions. The Sesderma Group
encompasses several notable
brands, including Sesderma,
Mediderma, Sophieskin, Dr.
Serrano, and Dermopartners,
specializing in third-party
manufacturing.
In 2008, Sesderma made history
with the introduction of complete
product lines utilizing the power
of nanotechnology. This
groundbreaking achievement
revolutionized the industry,
allowing ingredients to effectively
penetrate the skin's protective
layer, ensuring their utmost
efficacy. Unlike superficial
offerings from other cosmetic
lines, Sesderma's liposomal
products go beyond mere
hydration and comfort, providing
comprehensive repair and
protection throughout all layers of
the skin.
The ethos of “Listening to your
skin” encapsulates the essence of
Sesderma, a laboratory devoted to
nurturing skin health and beauty.
Through dermatological
innovation and an unwavering
dedication to the well-being of the
skin, Sesderma continues to
redefine the boundaries of the
industry, leaving a lasting impact
on the lives of countless
individuals.
16 | November 2023

Inspiring Success Through Human Values and Positive Attitude
Dr. Serrano consistently emphasizes that, above all else, he is a
person who values human qualities. He takes pride in being a
man of simple and generous values, and he genuinely cares
about the society in which he lives. These are the core values
that he seeks in the individuals he works with, placing them
above mere aptitude or skill. As he often says, "It is easier to
train aptitude than attitude.”
When individuals possess the right attitude, they exhibit
motivation and adaptability, making them open to learning
new skills. Dr. Serrano believes that with the right attitude and
sufﬁcient effort, most new skills can be mastered swiftly. He
understands that a positive attitude is a crucial factor in
personal and professional growth, and he values individuals
who embrace this mindset.

Dr. Rupert Ecker
18 | November 2023

Prioritizing Diversity, Collaboration, and Ethical
Conduct in Advancing Scientiﬁc Progress

Journey of Founding TG GLOBAL
Originally aspiring to become an astronomer,
Dr. Ecker eventually turned his attention to the
microcosmos and pursued a degree in cell
biology. He is a co-inventor of the TissueFAXS
technology and played a pivotal role in the
establishment of TG and its international
offices and subsidiaries, serving as CEO and
CSO of TG GLOBAL. During his post-
doctoral research position at the Kplus
Competence Centre for BioMolecular
Therapeutics, which was a joint venture
between University of Vienna and the Novartis
Research Centre, he co-founded the company.
As a student, Dr. Ecker's goal was to contribute
to scientific progress, and he found his personal
way of achieving this goal through TG. Over
the past 20 years, the company has not only
built a strong product portfolio but also made a
significant scientific impact, with over 2,500
scientific studies published in approximately
800 peer-reviewed journals that utilized TG's
technology in various ways. The scientific
applications of TG's technology range from
basic research to clinical implementation
studies, from bone marrow to brain, from cell
cultures to solid tissue sections, covering the
entire spectrum of biomedical research from A
(like Atopic dermatitis) to Z (like Zika virus
infection). Dr. Ecker is proud to have played a
part in this success story.
Collaboration and Multidisciplinary
Expertise
TissueGnostics was established by researchers
out of a need for automation and quantification
of microscopic images. Throughout its history
of 20 years, collaborative research has been
integral to the company's success.
TissueGnostics has participated in more than
20 Austrian national collaborative research
projects and has been an industry partner to
seven major EU-funded Marie Skłodowska-
Curie Innovative Training Networks (ITN) as
well as other EU programs such as COST
Actions, Framework 6/7, HORIZON 2020, and
HORIZON EUROPE programs.
20 | November 2023

Dr. Ecker's personal biggest risk
was leaving academia and
venturing into entrepreneurship
by founding TissueGnostics. It
was like taking a leap of faith
into unknown waters to test not
only the temperature of the
water but also his ability to
swim. However, his company
has become a leading provider
of tissue image cytometry,
offering automated analysis of
tissue samples using computer
assistance and AI-driven
technology for medical research
and histopathology.
TissueGnostics serves as a one-
stop-shop for their customers'
needs in this ﬁeld.
From Academia to
Entrepreneurship

Heidi Lindner
Supporting Entities in the Pharmaceutical and Biotechnology Sectors
“The possibility of designing solid
and innovative legal strategies to
face the challenges of my clients
has always been a source of
professional inspiration.”
24 | November 2023

The Heidi Staircase
As a young child, Heidi Lindner
enjoyed arguing, debating, expressing
her opinions, and taking the lead. Her
decision to seek a career in law may
have been influenced by her feeling of
powerlessness in the face of injustices
as much as her rage. Since her first
year of high school, she has known that
she wants to follow this area of study.
She earned a master's degree from
Panamerican University, a
specialization in constitutional
litigation (Amparo) from the Supreme
Court of Justice of Mexico's Institute
of Judicial Specialization, and a
master's degree from George
Washington University.
As her career progressed, Heidi
eventually concentrated on the topic of
Life Sciences within Intellectual
Property Law, paying particular
attention to the most recent
developments in science and
technology. She worked for Baker &
McKenzie's Intellectual Property
Department for about eight years.
During that time, she also rose to the
position of local partner. She joined the
current company, which was formerly
known as Arochi, Marroquin &
Lindner, in 1994. She is a Senior
Partner and the head of the Patent
Litigation section of Arochi & Lindner,
and she has more than 35 years of
experience in intellectual property and
life sciences litigation and advising,
achieving favorable rulings in several
landmark cases for clients in the
pharmaceutical, biotechnology, and
medical device industries.
Arochi & Lindner
Arochi & Lindner is a well-known and
respected name in Latin American
intellectual property protection. It was
established in 1994 and has become a
prominent firm in large part because of
its innovative and customer-focused
mindset. It opened an office in Spain in
2011, and as a direct result of its
success, they are still expanding both
domestically and internationally today.
Offering high-profile legal counsel in
the fields of intellectual property, life
sciences, marketing and advertising,
civil and commercial litigation,
corporate and regulatory, and personal
data security, the company has more
than 27 years of experience.
It helps clients overcome the legal
challenges they face by providing clear
and accurate advice that recognizes
and minimizes risks, foresees and
resolves issues, and secures the highest
potential profit for the clients within
each business opportunity, market, or
industry.
Due to its unwavering commitment to
each project, it is famous for its client-
focused service delivery method that
generates results quickly and
effectively. This is made possible by
the firm's commitment to each project;
its thorough approach based on years
of experience across a range of practice
areas; the assertiveness and
competence of its associates; and its
excellent understanding of clients'
business objectives.

Jahanara
Jahanara
Miotto
28 | November 2023

People frequently claim that the
best business ideas come from
their own personal experiences.
If you can use the lessons you learn
from these experiences to change the
world for the better, then your business
will succeed. Jahanara Miotto,
President of Metrendalytics
Consultants, has worked in the life
science sector for over 25 years,
spanning a wide range of functions in
laboratory R&D and clinical
development. Throughout her career,
she has repeatedly been frustrated by
the lack of timely access to project,
operational, and financial information
needed to make better and more rapid
business decisions.
She would try to find all the
information she required by scouring
through various disjointed systems,
spreadsheets, and talking to team
members. Then, in order to have all the
information she required in one
location, she would have to spend even
more time entering it again into her
own central tracker. In order to keep
the information current, Jahanara had
to perform this time-consuming task
frequently. She also frequently
pondered why, given the state of
modern technology, there isn't a more
effective tool that automatically
combines all of this data into one
location, allowing for greater
understanding of the company, its
operations, products, services,
finances, and personnel. This is what
inspired her to found Metrendalytics
and develop the tools to aid in
resolving the problem.
But the tool doesn't solve the entire
issue on its own. It also requires
commitment and expertise in the field.
Anyone who has dealt with clinical
trial data knows how time-consuming
and labor-intensive it is to create
database structures and specifications,
validate programs, export data from
one system, import it into another, and
confirm the transfer, then apply quality
control procedures to the data at the
other end. Without the drive and
perseverance to see it through, such a
task can feel overwhelming.
Metrendalytics
Metrendalytics has the specialized
knowledge and comprehension of how
different types of data interact with one
another and with other types of data.
The team at Metrendalytics is
passionate and skilled in application
development, automation, security and
compliance, as well as cloud-based
solutions, which enables customers to
meet their business needs.
Metrendalytics also possesses the ideal
combination of practical industry
experience and knowledge. We can
build end-to-end workflow solutions
that provide key intelligence, present
timely status updates across your
studies, and insights to streamline
operational processes, including
visually rich analytics and dashboards,
because we understand the business,
according to Jahanara.
If you can help customers realize that
adapting and changing is actually in
their best interest, Jahanara believes
that obstacles can become
opportunities. One issue Jahanara
encountered early on was some
opposition to using cloud-based
systems rather than customary on-
premise ones. Conventional wisdom
held that on-premise systems were
more secure and, consequently, more
controllable. For these reasons, some
businesses were against cloud-based
systems. "However, as we have all
observed over the years, it turns out
that cloud-based systems have greater
security because the businesses that
host these systems absolutely depend
on this feature. The web services
companies would not be able to
operate without this level of security.

Kevin
MacRitchie
Serving the Protectors of the Country
“Of course, my team is amazing, and it is
both my honor to serve the US military
and be of service to my staﬀ, and every
member, of Tac cal Rehabilita on.”

In today's business environment,
the role of a CEO has evolved
into that of a transformational
agent. As the world around us
changes rapidly, CEOs must lead
their organizations in adapting
to new challenges and
opportunities. They must be
visionary leaders who can inspire
their teams to embrace change
and drive innovation.
I
34 | November 2023

CEOs must also be adept at identifying and implementing
new technologies and business models that can drive
growth and competitiveness. They must have a deep
understanding of their industry, as well as the broader
economic and societal trends that impact it.
Kevin MacRitchie is a magnetic executive leader who
possesses vast knowledge of leading sales and operations.
He acts as a catalyst for business growth and
transformation, talent nurturing, and exploration of new
markets. He has an outstanding record of steering cross-
functional teams, creating innovative business solutions
and services, enhancing productivity, fostering
responsibility, engaging employees, and achieving
substantial revenue growth. He is also a pioneer in
developing service ecosystems.
Way to Joining Executive League
Kevin MacRitchie joined the project as a pioneering early
adopter and concentrated on how technology would help
improve a company's operational eﬃciencies at the
University of Toledo. Together with improving the
organization from within and changing market dynamics,
he also focused on how the marriage of IT and ISOM
would foster new understanding. Through computer
programming and technologically operational problem-
solving, this program includes advanced courses in
arithmetic, statistics, economics, and logical reasoning.
Kevin was given assistance from Professor Joe Sass at the
university to begin as an intern in a program where he
applied his education and managed the introduction of
new technologies and hardware and software systems.
Kevin spent eight years working for a large mainframe
corporation that started embracing distributed computing.
Eventually, Cisco Systems hired him to architect
transformations for client networks. He served in a variety
of capacities and industries at Cisco, where he was the
youngest employee ever promoted to vice president.
Kevin joined Tactical Rehabilitation as COO in 2020 after
working at Cisco for a while. After then, because to his
considerable knowledge of operational excellence in the
healthcare and IT industries, he was appointed CEO in
2022.
Kevin emphasizes that leaders
should never stop learning. He
makes it a point to work
together with members of the
team at all levels, getting their
perspectives on various
aspects of the business, taking
feedback into account, and
comprehending the current
climate or culture within the
organization, as well as with
partners and vendors. He
makes an effort to recognize
each team member's potential
and uses that potential to
strengthen the team in
tandem with the health of the
company.
Collaboration with
the Team
Tactical Rehabilitation
Tactical Rehabilitation is a full-service DME
provider whose aim is to help those who serve the
country. It oﬀers active-duty military personnel,
veterans, and their families the best products and
services available.

A Legacy of Excellence in Retail
Distribution and Manufacturing
Mitch Gould, the accomplished
Founder and CEO of NPI, brings a
l e g a c y o f e x c e l l e n c e i n r e t a i l
distribution and manufacturing as a
third-generation professional. With an
impressive career spanning over 25
years, Mitch has honed his expertise
across diverse consumer product
categories, including lawn and garden,
hardware, sports nutrition, dietary
supplements, skincare, nutraceuticals,
cosmeceuticals, and beverages.
36 | November 2023

Mitch leveraged his entrepreneurial spirit and
extensive retail expertise to establish
Nutritional Products International, Inc. in
2007. The driving force behind the company was a clear
vision: to offer affordable guidance and support to small
and medium-sized brands, both domestic and
international. With his deep understanding of the industry,
Mitch recognized the common challenges faced by
numerous businesses, even those boasting exceptional
brands on a global scale. "I watch the latest retail and
economic trends, which benefit our clients as they plan to
entertheUS marketor expandsales here,"says Mitch.
Throughout his journey, Mitch has been a trusted
representative for esteemed organizations such as Igloo,
Rubbermaid, Sunbeam, Remington, Chapin, Paramount,
Miracle-Gro, Native Remedies, Flora Health, Steven
Seagal's Lightning Bolt, Body Basix, and Hulk Hogan's
extreme energy granules. His proven track record includes
successfully guiding a wide range of products from
concept to store shelves, with many earning prominent
features in renowned publications such as Time,
Newsweek, Sports Illustrated, People, US, U.S. News &
World Report, Men's Health, and Maxim. In addition to his
product expertise, Mitch has consistently demonstrated his
leadership acumen by building and managing high-
performingnationalsalesteamsthroughouthis career.
Mitch's remarkable industry insights have paved the way
for the successful entry of new entrepreneurs, major
corporations, and celebrity-branded products into coveted
markets and accounts across the country. Notable
achievements include securing placements for iconic
products like Steven Seagal's Lightning Bolt, Hulk
Hogan's "Hogan Energy" supplement, and Chuck Liddell's
Iceman RX in highly sought-after retailers such as
Walmart USA,Walmart International, Sam's Club, Costco,
GNC, Tree of Life, Albertson's, Amazon.com, Walgreens,
CVS, 7-Eleven,Target, USASports,VitaminWorld, Home
Depot,Lowe's, andMenards.
Collaboration lies at the heart of Mitch's success, as
evident in his partnerships with industry luminaries.
Noteworthy collaborations include his alliance with the
legendary eight-time Mr. Olympia Ronnie Coleman to
establish RonnieColemanNutrition.com, his joint venture
with Hulk Hogan for HoganNutrition.com, his partnership
with Roberto Clemente Jr. for PowerIce.com, and most
recently, his involvement with Tapout Nutrition. These
ventures reflect Mitch's commitment to driving innovation
andgrowth withintheindustry.
Unmatched ExpertiseandAll-In-One Solutions
NPI stands out from its competitors primarily due to its
expertise. Mitch began his career as a marketing and sales
agent for renowned companies such as Igloo,
Rubbermaid, Sunbeam, Remington, Chapin, Paramount,
Miracle-Gro, Native Remedies, and Flora Health.
Throughout his career, Mitch secured significant purchase
orders with major retail stores like Target, Walmart,
Lowe's, Costco, Walgreens, 7-Eleven, GNC, and CVS at
theirnationalheadquarters.
Mitch developed the "Evolution of Distribution" system
for NPI, a comprehensive solution that combines expert
services to enhance sales and introduce new brands in the
USA. NPI boasts a highly experienced team capable of
handling all aspects of sales and marketing. Mitch's focus
on pricing and speed to market has streamlined the sales
expansionandproductlaunchprocesses.
NPI provides a complete, all-in-one solution for product
launches in the United States. With its proprietary
"Evolution of Distribution" system, NPI has the capacity
to import, distribute, and promote products in various
sectors, including food, drug, mass, convenience stores,
warehouse clubs, and military channels. Effectively
acting as the overseas clients' US headquarters, NPI
allows clients to take advantage of its services at a
reasonableprice.
38 | November 2023

Mitch emphasizes how NPI can help clients achieve their
goal of entering the US market, offering a range of
services that eliminate the need for recruiting sales
representatives, administrative assistants, warehouse
space, marketing expertise, logistical knowledge, and
FDA compliance. The "Evolution of Distribution"
platform proves invaluable in reducing costs for NPI
clients and facilitating their successful entry into the US
market.
Navigating the Changing RetailLandscape
The COVID-19 pandemic had a profound impact on the
retail industry, accelerating the growth of e-commerce.
While online shopping had been steadily increasing, the
pandemic compelled customers to make in-person
purchases of brands they had previously only bought
online. To adapt to these changing consumer behaviors,
retailers introduced new services such as curbside pickup,
next-andsame-daydelivery, andmore.
For brand manufacturers, especially those who primarily
operated online, these changes presented new challenges.
Managing the supply chain became increasingly difficult
as they needed to meet the demand if a retail store decided
to carry their brands.As an example, one customer shared
with Gould that the bottle cap they had been using faced a
backorder of nine months, forcing them to switch
suppliers. The importance of having an online presence,
which was already significant before the pandemic,
becameevenmorecriticalduringthehealthemergency.
Many businesses, particularly startups, excel at
developing innovative products but lack the necessary
personnel to effectively market and sell them. These
companies require a team of talented and qualified
employees to navigate the complexities of the retail
industry.At NPI, a skilled sales team is in constant contact
withretailcustomersthroughouttheyear.

Leading the Transformation of The Family Firm from
a Traditional Pharmaceutical Company to a Successful
Transnational Corporation Focused on Natural
Consumer Healthcare
It's a transformation that we are very
proud of, by the way. It's been an
extraordinary journey in which I've had
the best years of my professional life, like
many others who are part of this great
family. And we still have a lot of
challenges ahead of us!"
42 | November 2023

CEO | Uriach

People want to live longer, but they
also want to live better, with
improved health, well-being, and
quality of life. And they understand
that achieving this requires a
multifaceted approach that includes
diet, physical activity, sport, rest,
sleep, body care, emotions, mind,
and spirit.
This humanization and integration of
many disciplines around well-being
is undoubtedly the most significant
challenge confronting the healthcare
industry, in addition to other more
operational aspects such as
omnichannel, the growth of e-
commerce, personalization,
distribution, regulatory issues,
sustainability, direct consumer
relationships, and so on.
Oriol Segarra is a leadership and
change management expert with over
20 years of business experience in
multinational pharmaceutical firms.
As Uriach's Chief Executive Officer,
he oversaw the pharmaceutical
company's development from a
traditional pharmaceutical company
to a successful transnational
corporation focus on natural
consumer healthcare.
Uriach is a corporation that thinks
that harnessing the power of nature is
the best (and most sustainable)
approach to caring for human health
and well-being. This is why Uriach is
solely dedicated to natural consumer
healthcare. Its purpose is to have a
beneficial influence on people's
health and lives while also striving to
improve the earth as a whole. It
provides the greatest natural goods to
consumers, based on sound research
and creativity.
With a history of over 182 years,
Uriach's notable worldwide
trademarks include Aquilea,
Fisiocrem, Laborest, Aerored, Fave
de Fuca, Utabon, Biodramina, and
Halibut, with a presence in the major
European markets. The company's
headquarters are presently located in
Spain, Portugal, Italy, Germany,
Austria, Switzerland, and Romania.
Life Outside of the Workplace
Oriol was born in Barcelona in 1971
and is the father of two children.
Oriol defines himself as an
inquisitive, restless, and ambitious
individual who is always looking for
new reasons, challenges, and
learning opportunities in order to
improve professionally and
personally. He attended ESADE,
Harvard, Stanford, Singularity
University, and IMD, among other
business institutions.
P
44 | November 2023

PAUL
EDALAT
Revolutionizing Medication Management for
Patient Safety and Well-Being
With a distinguished career
spanning over 30 years in the
pharmaceutical and
nutraceutical industries, Paul Edalat is a true
visionary driven by his passion for
transforming the healthcare industry to
better serve patients and providers. As the
Chairman, Founder, and CEO of Vivera, Mr.
Edalat is on a mission to improve the lives
and well-being of patients worldwide,
concentrating on future-focused medicine
and drug delivery to ensure equitable health
opportunities for all.

The Journey from Fitness
Entrepreneur to Healthcare
Innovator
From a young age, Mr. Edalat was
keenly interested in tennis,
weightlifting, and overall health and
wellness. Using his entrepreneurial
skills and experiences, he significantly
impacted the rapidly growing fitness
and wellness industries.
However, when his brother Peter was
diagnosed with Hodgkin's lymphoma
in 2004, Mr. Edalat's priorities shifted.
He witnessed firsthand the challenges
and limitations of the healthcare
system, particularly in terms of patient-
centric care and access to safe
treatment options.
Peter's doctor prescribed him high
doses of opioids to manage his
chemotherapy-induced pain. He
quickly built up a tolerance to his
medication and, due to the lack of
safety measures, began to exceed his
prescribed dosage, ultimately
developing an addiction.
It was heartbreaking for Mr. Edalat to
witness his brother struggle with
cancer and addiction. This experience
led him to recognize the need for a
more controlled approach to
prescribing and dispensing
medications, which motivated him to
establish Vivera.
With Dr. Mehdi Hatamian, one of Mr.
Edalat's brilliant, long-time friends, he
developed ZICOH, a patented smart
drug delivery system for prescription
medications.
ZICOH is designed to dispense precise
medication doses while minimizing the
risk of misuse. It works in conjunction
with ZICOH Connect™, a cloud-based
software system with robust data
organization and AI capabilities that
provide real-time prescribing data and
actionable insights for medication
adherence and compliance.
The groundbreaking technology,
ZICOH, aims to provide patients with
the right medication dose at the right
time to ensure compliance and deter
the consequences of potentially
becoming addicted. Because
medications are locked in ZICOH
devices and only accessible by the
patient, the system helps curb the
potential for the diversion of
prescription drugs.
Vivera's Growing Portfolio
Mr. Edalat cofounded Vivera to
develop non-addictive pain
management solutions through its
pharmaceuticals and medical device
divisions. Over time, the Company has
diversified into several divisions
geared toward improving patient care.
Vivera Technologies and Vivera
Medical Devices are dedicated to
creating cutting-edge technology to
revolutionize patient care. The core
product line of Vivera Technologies is
ZICOH.
Vivera BioSciences focuses on
developing medications for various
conditions using its patented
TABMELT technology for sublingual
drug delivery.
Vivera Neurosciences is dedicated to
investigating and developing therapies
for disorders of the central nervous
system, such as psychiatric,
neurological, and fluency disorders, to
enhance the lives of patients and offer
better options for healthcare
professionals.
Vivera Advanced Diagnostics uses its
Lab Information Management System
(LIMS), LabPort, to deliver patients
quick and reliable diagnostic and
wellness test results.
The Company has become a multi-
faceted business dedicated to
improving patient care and meeting
various medical demands.
Global Leadership in Patient-
Centric Healthcare Solutions
Mr. Edalat envisions Vivera as a
worldwide leader in delivering
innovative, patient-centric healthcare
solutions that are non-addictive.
By focusing on advanced diagnostics,
cutting-edge research and
development, and the latest
technologies, the Company strives to
expand its product portfolio
continually and enhance patient
outcomes.
Establishing strategic partnerships with
global partners is crucial to Vivera's
approach. Through these partnerships,
the Company aims to collaborate on
research, development, and distribution
of its products and services. This will
enable Vivera to expand its market
reach and leverage its partners'
strengths to enhance its global
presence.

Delivering Novel Therapies
to Improve the Health and
Quality of Life of
patients everywhere
Raman
Singh
50 | November 2023

T
he previous few years have compelled leadership
techniques to modify and adapt, especially as the
pandemic pushed for mandatory work from home
policies. Numerous organizational structures and
hierarchies have also been questioned, along with
traditional leadership styles. As a result, working standards and
values have had to change as well, and to be a persuasive leader,
you must adapt in response to your environment. Leaders have had
to adapt and make their organizations or environments more
inclusive in order to be effective in our present work environment.
This has probably led to many ﬁrms functioning better than they
ever have.
Raman Singh, the founder and CEO of Juniper Biologics, has
extensive knowledge in the pharmaceutical and healthcare sectors.
He formerly served as CEO of Mundipharma, a large global
pharmaceutical ﬁrm with a focus on research. Additionally, he led
initiatives in research and development to look at how consumer
goods may assist nations in halting the COVID-19 virus’s rapid
growth. To demonstrate that certain Betadine medications (part of
the Mundipharma portfolio) might kill the COVID-19 virus in 15 and
30 seconds, laboratory testing was started at Duke-NUS and other
labs across the world. Raman was motivated to create Juniper
Biologics after working in various places and observing the
disparities in healthcare as well as the effects his work had on a
worldwide scale. His mission is to make innovative medications
available to those most in need.

“We want to be the ﬁrst to
commercialise and create
access to much needed
treatments to improve the
quality of life of patients
everywhere.”
52 | November 2023

Steeping in Entrepreneurship
Raman realized the impact his work
may have on people's health on a
worldwide scale after working on the
research and development projects to
stop the spread of COVID-19. That is
what motivated him to look for novel
treatments that might prolong the
lives of patients with crippling
diseases like cancer. Raman's focus
on enhancing access to important and
inexpensive medications as well as
offering cutting-edge treatments to
improve patients' quality of life was
necessary, even though creating a
successful firm is difficult. He
observes that large pharmaceutical
corporations frequently prioritize
treating millions of patients over
treating a few hundred or thousand
people suffering from a rare
condition. He knew this is where
Juniper Biologics could make a
profound impact, because everyone
deserves access to treatments to
improve the quality of their lives.
Previous experience has also taught
Raman that hard work and resilience
will enable him to create an
organization that has significant
value. He knew that a strong
foundation of ESG values takes
Juniper Biologics to the next level,
which would ultimately allow him to
bring innovative medicines to people.
The Company
Juniper Biologics is a science-led
specialty healthcare company
focused on commercializing novel
therapies. Founded in 2021 and
globally headquartered in Singapore,
our mission is to make a real impact
on the lives of patients by improving
accessibility to the next generation of
treatments. It brings innovative
medical treatments to patients around
the world in the areas of oncology
and oncology supportive care, rare
and orphan diseases, and gene
therapy.
The company takes care to
participate in as many pertinent
industry events as it can, as both a
sponsor and an exhibitor, in order to
keep ahead of the competition.
Additionally, Juniper Biologics
makes a point of networking with as
many key figures in the scientific and
medical fields as it can. The business
is a Platinum Sponsor of the next
European Society for Medical
Oncology (ESMO) in Singapore as
well as the 2023 International Breast
Congress in Singapore. It also
sponsored the Excellence in
Oncology Care conference in Dubai.
This demonstrates its dedication and
solidifies its position as a respectable
business in the sector.
In the therapeutic areas it has chosen,
Juniper Biologics is always doing
research and looking for the most
cutting-edge therapies. Raman states,
“We want to be the first to
commercialise and create access to
much needed treatments to improve
the quality of life of patients
everywhere.”
Changing the Pharma Industry
from Within
Juniper Biologics has accomplished
significant milestones since its
inception in 2021. The license rights
to create and market TG-C LD, the
first cell-mediated gene therapy in
the world for the treatment of knee
osteoarthritis, were recently acquired
for up to USD $600 million. An
estimated 300 million patients in
Asia Pacific, the Middle East, and
Africa will be able to get this
medicine thanks to this initiative. In
addition, Juniper Biologics
completed six license agreements in
the last year and added Aloxi,
Akynzeo, and Anamorelin to its
portfolio of cancer supportive care
products, a market with a significant
unmet need worldwide.
In addition, Juniper Biologics will
shortly introduce Ledaga, a topical
gel medication for treating MF-
CTCL, the most prevalent cutaneous
T-cell lymphoma. It has secured the
licensing and marketing
authorizations to promote and sell it
in Australia, Southeast Asia, and the
Middle East. These acquisitions and
treatments are invaluable to patients
who suffer from these diseases.
A Leader's Way and His Vision
As the CEO of Juniper Biologics, it
is Raman's responsibility to move the
company's growth of Juniper
Biologics in the right direction – one
that is sustainable, innovative, and
stays true to the company's mission
and ESG values. He is in charge of
making sure that the teams in each of
the important markets for the firm are
connected, appreciated, and still
concentrating on the unmet medical
requirements of patients and the best
ways to aid them. Making calls and
checking in with his staff all across
the world is another aspect of
Raman's daily schedule that makes
him the happiest. A big part of what
Raman does is not just about the task
but also about the people.

World’s Influential Leaders Making A Footprint in Pharma and Biotech, 2023.pdf

World’s Influential Leaders Making A Footprint in Pharma and Biotech, 2023.pdf

Recommended

Recommended

More Related Content

Similar to World’s Influential Leaders Making A Footprint in Pharma and Biotech, 2023.pdf

Similar to World’s Influential Leaders Making A Footprint in Pharma and Biotech, 2023.pdf (20)

More from Worlds Leaders Magazine

More from Worlds Leaders Magazine (20)

Recently uploaded

Recently uploaded (20)

World’s Influential Leaders Making A Footprint in Pharma and Biotech, 2023.pdf